Novel Candidates for the Drug Treatment of Alzheimer's Disease

Guest Editors:

Dr. Himanshu Narayan Singh

Dr. Maria de Lourdes Pereira

Prof. Dr. Bechan Sharma

Dr. Vishnu Swarup

Deadline for manuscript submissions:
closed (30 November 2023)

Message from the Guest Editors

Dear Colleagues,

Alzheimer's disease (AD) is irreversible and the most common neurodegenerative disease worldwide, which is identified by senile dementia, characterized by progressive memory and neuronal loss, combined with cognitive impairment. There is no permanent cure available for AD. The primary aim of most of the therapeutic strategies for AD is to improve the quality of daily life of the patients, especially targeting their memory, eenhancing their independence. These therapeutics work either by easing the symptoms or by slowing down the progression of the disease. Inventing new therapeutic molecules as well as drug repurposing become crucial to treat patients. In order to identify and evaluate new treatments for AD, it is critical to utilise more rigorous, evidence-based approaches of drug development and clinical trials, ensuring the mechanisms of action are confirmed and trial designs optimised. We invite research, review and correspondence articles on novel approaches/molecules/therapeutic strategies for treatment of Alzheimer's disease.

mdpi.com/si/164237

Special Issue

pharmaceuticals

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e
Bioquímica (DQB) e Centro de
Química e Bioquímica (CQB),
Faculdade de Ciências,
Universidade de Lisboa (FCUL),
Rua Ernesto de Vasconcelos,
Campo Grande,Edifício C8, 5º
Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us